Altis Biosystems

About Altis Biosystems

Altis Biosystems operates in the biotechnology sector, focusing on creating advanced in vitro platforms for drug development. The company serves pharmaceutical and biotech firms, providing them with a unique stem cell-derived platform called RepliGut. This platform replicates the human small intestine and colonic epithelium, enabling more biologically relevant screening of compounds, disease modeling, and microbiome research. By mimicking native human biology, RepliGut produces more accurate and reproducible data, which enhances clinical trial performance and reduces the need for animal testing. Altis Biosystems' business model revolves around offering scalable, high-throughput screening services and access to an extensive biobank, allowing clients to test thousands of compounds efficiently. The company generates revenue through service contracts and licensing agreements with its clients. Altis Biosystems is positioned in the market as a key player in the development of safer, more effective drugs, reducing both time and cost in the drug development process.